Goldman Sachs Put 800 REGN 17.01..../ DE000GZ8MV00 /
| 6/19/2024 11:00:00 AM | Chg.0.000 | Bid11:46:31 AM | Ask11:46:31 AM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.080EUR | 0.00% | 0.080 Bid Size: 10,000 |
0.130 Ask Size: 5,000 |
Regeneron Pharmaceut... | 800.00 - | 1/17/2025 | Put |
GlobeNewswire
6/16
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...
GlobeNewswire
6/11
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire
5/31
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
5/31
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
5/23
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire
5/20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
5/17
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...
GlobeNewswire
5/13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
5/8
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire
4/29
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire
4/25
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire
4/24
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire
4/22
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...
GlobeNewswire
4/7
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...
GlobeNewswire
4/1
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...
GlobeNewswire
3/13
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientif...
GlobeNewswire
3/11
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High C...
GlobeNewswire
3/8
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) a...
GlobeNewswire
2/23
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflam...
GlobeNewswire
2/21
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Re...
